Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~A subject must meet the following inclusion criteria at screening (visit 1) and at randomization (visit 2) to be considered for enrollment in the study:~* Male or female subjects between the ages of 18 and 40.~* Healthy male or female subjects as determined by medical history, physical examination, and judgment of the investigator.~* Male or female subject who is considered biologically capable of having children must agree to commit to the use of a reliable method of birth control for the duration of the study and for 30 days after early discontinuation. A subject is still biologically capable of having children, even if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.~In addition a subject must meet the following inclusion criteria at randomization (visit 2) to be considered for enrollment in the study. The referred blood and urinalysis tests (inclusion criterion 5) will be performed on a blood and urine sample taken at visit 1:~* Female subjects of childbearing potential with a negative urine pregnancy test prior to study drug administration. Note: this criterion will apply to each vaccination visit and to the last study visit.~* Laboratory blood and urinalysis tests results within the per-protocol normal ranges.~* Able to be contacted by telephone during the study period. Note: this criterion will apply to each study visit.~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): rLP2086 vaccine 60 mcg
- 2 (Type: EXPERIMENTAL): rLP2086 vaccine 120 mcg
- 3 (Type: EXPERIMENTAL): rLP2086 vaccine 200 mcg
- 4 (Type: ACTIVE_COMPARATOR): Tdap vaccine - normal saline - normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).